FATE ▼ -2.5% - Fate Therapeutics, Inc. $FATE - Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026 Fate Therapeutics fell 2.5% today despite news that the company has been selected for four presentations on its off-the-shelf CAR T-cell portfolio in autoimmune disease at the ACR Convergence 2026 conference. The decline suggests investors may view conference presentations alone—without accompanying clinical trial results or regulatory approvals—as insufficient catalyst for near-term stock movement. 16-SEP-2026 07:00 AM ET